This trial is looking at the effectiveness of Quad Shot (QS) radiation therapy (RT) to relieve symptoms in patients with advanced non-small-cell lung cancer (NSCLC). The main outcome that is to be measured is the occurrence of side effects over the course of 3-months. This trial is being carried out in New Jersey and New York, US.
NSCLC is the most common form of lung cancer. NSCLC is responsible for 85% of all lung cancer diagnoses worldwide. NSCLC is usually treated with chemotherapy, surgical removal of tumors, and radiotherapy. Advanced NSCLC is lung cancer that has spread or is resistant to treatment. Radiotherapy can be used to reduce the symptom occurrence from NSCLC. QS-RT uses fewer days to deliver the RT. This might be less disruptive for patients who are already receiving other treatments.
This trial is evaluating the safety of QS-RT in patients with advanced NSCLC who are on systemic (whole-body) therapy. The main outcome to be measured is the occurrence of side effects in patients. over 3 months.
Who are they looking for?
This trial is looking to recruit 36 patients with advanced NSCLC. Patients must have confirmed NSCLC, be receiving a systemic treatment such as chemotherapy or immunotherapy, and have lung cancer symptoms such as cough, difficulties breathing, coughing blood. Patients of reproductive age must agree to use effective birth control during the study.
Patients will be excluded from this trial if they have received previous RT or if they have serious medical conditions that may worsen with RT.
How will it work
There is one group in this study. All participants will be treated with up to 3 cycles of QS-RT. This will be given within 1 week of patients receiving chemotherapy. The next RT cycle will be given after a break of 21-28 days.
Side-effect occurrence will be measured over a time-frame of 3-months.